Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-694-6200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableOptionable
Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions
What is Arcus Biosciences' stock symbol?
Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."
How were Arcus Biosciences' earnings last quarter?
Arcus Biosciences Inc (NYSE:RCUS) released its quarterly earnings data on Thursday, November, 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.13. The business earned $4.29 million during the quarter, compared to the consensus estimate of $1.40 million. View Arcus Biosciences' Earnings History.
When is Arcus Biosciences' next earnings date?
What price target have analysts set for RCUS?
4 analysts have issued 12-month price objectives for Arcus Biosciences' shares. Their predictions range from $18.00 to $22.00. On average, they expect Arcus Biosciences' stock price to reach $19.75 in the next twelve months. This suggests a possible upside of 105.1% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.
What is the consensus analysts' recommendation for Arcus Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.
Has Arcus Biosciences been receiving favorable news coverage?
Media coverage about RCUS stock has been trending very positive this week, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arcus Biosciences earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Are investors shorting Arcus Biosciences?
Arcus Biosciences saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,048,556 shares, an increase of 71.1% from the December 14th total of 1,197,327 shares. Based on an average daily trading volume, of 500,609 shares, the days-to-cover ratio is currently 4.1 days. Approximately 8.6% of the company's stock are short sold. View Arcus Biosciences' Current Options Chain.
Who are some of Arcus Biosciences' key competitors?
Some companies that are related to Arcus Biosciences include Portola Pharmaceuticals (PTLA), PTC Therapeutics (PTCT), Corcept Therapeutics (CORT), Mallinckrodt (MNK), Pacira Pharmaceuticals (PCRX), Vanda Pharmaceuticals (VNDA), Zai Lab (ZLAB), Theravance Biopharma (TBPH), Enanta Pharmaceuticals (ENTA), Biohaven Pharmaceutical (BHVN), The Medicines (MDCO), Cambrex (CBM), Prestige Consumer Healthcare (PBH), Aimmune Therapeutics (AIMT) and Arrowhead Pharmaceuticals (ARWR).
Who are Arcus Biosciences' key executives?
Arcus Biosciences' management team includes the folowing people:
- Dr. Terry Rosen Ph.D., Co-Founder, CEO & Director (Age 59)
- Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 61)
- Ms. Jennifer Jarrett M.B.A., COO & CFO (Age 48)
- Mr. Steven Chan, VP of Fin., Corp. Controller & Principal Accounting Officer (Age 47)
- Dr. Stephen Young Ph.D., VP of Technology (Age 50)
When did Arcus Biosciences IPO?
(RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.
How do I buy shares of Arcus Biosciences?
Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arcus Biosciences' stock price today?
One share of RCUS stock can currently be purchased for approximately $9.63.
How big of a company is Arcus Biosciences?
Arcus Biosciences has a market capitalization of $428.09 million.
What is Arcus Biosciences' official website?
How can I contact Arcus Biosciences?
Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]
MarketBeat Community Rating for Arcus Biosciences (NYSE RCUS)
MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote "Outperform" if you believe RCUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
